Phase II study of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group Study.
D015250:Aclarubicin; D000328:Adult; D000368:Aged; D001388:Aziridines / Q000009:adverse effects / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D016227:Benzoquinones; D001932:Brain Neoplasms / Q000556:secondary; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use; D011897:Random Allocation
D001388:Aziridines; D001389:Azirines; D016227:Benzoquinones; D009279:Naphthacenes; D015250:Aclarubicin; C029108:diaziquone